25-Gauge microincision vitrectomy to treat vitreoretinal disease in glaucomatous eyes after trabeculectomy

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Purpose. To determine the feasibility of using 25-gauge microincision vitrectomy surgery (25GMIVS) to treat vitreoretinal disease in glaucomatous eyes which have previously undergone trabeculectomy (TLE). Methods. A consecutive, interventional case series. We performed 25GMIVS in 15 glaucomatous eyes that had undergone TLE. Follow-up period was 11.5 months. Results. 25GMIVS was successfully used and led to improvement in visual acuity (P < 0.01). We performed 25GMIVS for proliferative diabetic retinopathy with neovascular glaucoma in 53% of eyes (8 of 15). Although 3 eyes needed further TLE following 25GMIVS, final IOP was below 21 mmHg in all eyes except one eye (93%) and was comparable to pre-25GMIVS IOP (P = 0.20) without an increase in the number of glaucoma medications (P = 0.14). Conclusions. 25GMIVS is a feasible treatment for vitreoretinal disease in eyes with preexisting TLE, effective in both significantly improving BCVA and preserving the filtering bleb, while not excluding further glaucoma surgery.

Original languageEnglish
Article number306814
JournalJournal of Ophthalmology
Volume2014
DOIs
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of '25-Gauge microincision vitrectomy to treat vitreoretinal disease in glaucomatous eyes after trabeculectomy'. Together they form a unique fingerprint.

Cite this